Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration.
|Abstract||To evaluate the efficacy and safety of topical isopropyl unoprostone (IU) in treating macular atrophy in age-related macular degeneration (AMD) patients.|
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
|Publication Year Start||2017-01-01|
PMID- 28328847 OWN - NLM STAT- MEDLINE DA - 20170322 DCOM- 20170410 LR - 20170410 IS - 1536-5964 (Electronic) IS - 0025-7974 (Linking) VI - 96 IP - 12 DP - 2017 Mar TI - Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration. PG - e6422 LID - 10.1097/MD.0000000000006422 [doi] AB - BACKGROUND: To evaluate the efficacy and safety of topical isopropyl unoprostone (IU) in treating macular atrophy in age-related macular degeneration (AMD) patients. METHODS: Fifty-two AMD patients with macular atrophy were included and randomly assigned (1:1) to the treatment (topical 0.15% IU) or placebo group. Subjects used study eye drops 3 times a day for 54 weeks. The macular atrophy was documented on fundus autofluorescence photographs and measured using RegionFinder. The enlargement rate of macular atrophy and the changes in visual acuity were examined statistically between baseline and 54 weeks. RESULTS: Forty-eight subjects were included in the analyses because 4 subjects withdrew from the study. The differences between the IU and placebo groups in mean and median area of macular atrophy were not statistically significant at baseline. The baseline median lesion size of macular atrophy was 2.33 mm in the IU group and 1.63 mm in the placebo group (P = 0.51). The intergroup difference in the enlargement ratio of macular atrophy (21 +/- 15% in the IU group and 111 +/- 96% in the placebo group) was statistically significant (P < 0.001). Additionally, visual acuity tended to improve over baseline in the IU group. No serious adverse events were observed. CONCLUSIONS: Topical IU therapy is safe and effective for treating macular atrophy in AMD patients. FAU - Shiragami, Chieko AU - Shiragami C AD - aDepartment of Ophthalmology, Kagawa University Faculty of Medicine, Kagawa bDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto cDepartment of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Miyake, Masahiro AU - Miyake M FAU - Fujiwara, Atsushi AU - Fujiwara A FAU - Morizane, Yuki AU - Morizane Y FAU - Tsujikawa, Akitaka AU - Tsujikawa A FAU - Yamashita, Ayana AU - Yamashita A FAU - Shiraga, Fumio AU - Shiraga F LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Antihypertensive Agents) RN - 5M161S5O5P (isopropyl unoprostone) RN - B7IN85G1HY (Dinoprost) SB - AIM SB - IM MH - Administration, Topical MH - Aged MH - Aged, 80 and over MH - Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use MH - Dinoprost/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use MH - Disease Progression MH - Double-Blind Method MH - Female MH - Fluorescein Angiography MH - Humans MH - Macular Degeneration/*drug therapy MH - Male MH - Middle Aged MH - Visual Acuity PMC - PMC5371484 EDAT- 2017/03/23 06:00 MHDA- 2017/04/11 06:00 CRDT- 2017/03/23 06:00 AID - 10.1097/MD.0000000000006422 [doi] AID - 00005792-201703240-00050 [pii] PST - ppublish SO - Medicine (Baltimore). 2017 Mar;96(12):e6422. doi: 10.1097/MD.0000000000006422.
<?xml version="1.0" encoding="UTF-8"?> <b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" > </b:Sources>